Blood cancers

Inotuzumab listed on PBS for ALL

Inotuzumab (Besponsa) will be available on the PBS from 1 May for patients with acute lymphocytic leukaemia (ALL). The new PBS listing for the an anti-CD22 antibody Therapy, announced as part of the 2019 Federal Budget, will be for the treatment of relapsed or refractory CD22 positive B-cell precursor ALL. The listing will mean that ...

Already a member?

Login to keep reading.

© 2021 the limbic